<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE article  PUBLIC "-//NLM//DTD Journal Publishing DTD v3.0 20080202//EN" "http://dtd.nlm.nih.gov/publishing/3.0/journalpublishing3.dtd"><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" dtd-version="3.0" xml:lang="en" article-type="research article"><front><journal-meta><journal-id journal-id-type="publisher-id">OJOG</journal-id><journal-title-group><journal-title>Open Journal of Obstetrics and Gynecology</journal-title></journal-title-group><issn pub-type="epub">2160-8792</issn><publisher><publisher-name>Scientific Research Publishing</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.4236/ojog.2020.10110146</article-id><article-id pub-id-type="publisher-id">OJOG-104427</article-id><article-categories><subj-group subj-group-type="heading"><subject>Articles</subject></subj-group><subj-group subj-group-type="Discipline-v2"><subject>Medicine&amp;Healthcare</subject></subj-group></article-categories><title-group><article-title>
 
 
  Pattern of Presentation and Associated Morbidities of Women Presenting with Postmenopausal Bleeding
 
</article-title></title-group><contrib-group><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>Johnbosco</surname><given-names>E. Mamah</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref><xref ref-type="corresp" rid="cor1"><sup>*</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>Kanario</surname><given-names>A. Onyebuchi</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>Robinson</surname><given-names>C. Onoh</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>Love</surname><given-names>Okafor</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>Zubaida</surname><given-names>Aliyu</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref></contrib></contrib-group><aff id="aff2"><addr-line>Homerton University Hospital, London, UK</addr-line></aff><aff id="aff1"><addr-line>Federal Teaching Hospital Abakaliki, Ebonyi State, Nigeria</addr-line></aff><pub-date pub-type="epub"><day>06</day><month>11</month><year>2020</year></pub-date><volume>10</volume><issue>11</issue><fpage>1631</fpage><lpage>1636</lpage><history><date date-type="received"><day>24,</day>	<month>October</month>	<year>2020</year></date><date date-type="rev-recd"><day>24,</day>	<month>November</month>	<year>2020</year>	</date><date date-type="accepted"><day>27,</day>	<month>November</month>	<year>2020</year></date></history><permissions><copyright-statement>&#169; Copyright  2014 by authors and Scientific Research Publishing Inc. </copyright-statement><copyright-year>2014</copyright-year><license><license-p>This work is licensed under the Creative Commons Attribution International License (CC BY). http://creativecommons.org/licenses/by/4.0/</license-p></license></permissions><abstract><p>
 
 
  Background:
   Postmenopausal bleeding (PMB) is caused mainly by benign disorders; however it is sometimes caused by endometrial cancer. <b>Aim:</b> We here attempted to determine what conditions account for PMB in an outpatient clinic of a University hospital in London. <b>Methodology:</b> Study subjects consisted of 179 patients with PMB who were referred to us from July to December 2019. Sociodemographic data including patient’s age, risk factors, diagnosis and management were reviewed. Underlying conditions where determined. <b>Results:</b> Of 179 subjects, the following findings were made: 1) Age 59.63 &#177; 8.3 (mean and standard deviation). 2) Parity; multiparity, 57.0% (mean &#177; 1.67). 3) First episode of PMB, 77.1%. 4) The most frequently observed risk factor; obesity 34.6%. 5) The following accounted for PMB (diagnosis in order of incidence rate); genital atrophy 37.4%, submucosal fibroid 28.5%, endometrial polyp 20.7%, endometrial hyperplasia 6.7%, and endometrial cancer 5.6%. All patients were treated appropriately. We did not determine the prognosis of patients with endometrial cancer. <b>Conclusion:</b> Although the incidence of rate among women with PMB has already been reported, its reconfirmation in a single facility is important for making policies in the treatment of PMB.
 
</p></abstract><kwd-group><kwd>Endometrial Cancer</kwd><kwd> Postmenopausal Bleeding</kwd></kwd-group></article-meta></front><body><sec id="s1"><title>1. Introduction</title><p>Vaginal bleeding after the menopause is a concerning health issue in postmenopausal women [<xref ref-type="bibr" rid="scirp.104427-ref1">1</xref>]. Postmenopausal bleeding (PMB) is defined as any bleeding from the female genital tract after after the menopause [<xref ref-type="bibr" rid="scirp.104427-ref2">2</xref>] [<xref ref-type="bibr" rid="scirp.104427-ref3">3</xref>] [<xref ref-type="bibr" rid="scirp.104427-ref4">4</xref>]. The source of bleeding is commonly the uterus but may also be from the cervix, vagina, vulva or related to pathologies of the ovaries and tubes.</p><p>Postmenopausal bleeding accounts for about 5% of Gynaecological referrals [<xref ref-type="bibr" rid="scirp.104427-ref4">4</xref>]. In the majority, the cause is benign but may also indicate a sinister pathology including endometrial cancer. Endometrial cancer is diagnosed in 3% - 10% of women presenting with PMB [<xref ref-type="bibr" rid="scirp.104427-ref2">2</xref>] [<xref ref-type="bibr" rid="scirp.104427-ref3">3</xref>] [<xref ref-type="bibr" rid="scirp.104427-ref4">4</xref>]. Investigating women with postmenopausal bleeding is good clinical practice because endometrial cancer is the most common gynaecological malignancy in developed countries; long term survival depends on early diagnosis and treatment [<xref ref-type="bibr" rid="scirp.104427-ref5">5</xref>].</p><p>Causes of PMB include genital tract atrophy, endometrial hyperplasia, endometrial polyps, endometrial cancer, cervical pathologies including cervical cancer, hormone replacement therapy, ovarian and tubal pathologies [<xref ref-type="bibr" rid="scirp.104427-ref6">6</xref>] - [<xref ref-type="bibr" rid="scirp.104427-ref14">14</xref>]. By far the commonest cause is genital tract atrophy, although endometrial cancer is the most serious differential diagnosis and should be excluded [<xref ref-type="bibr" rid="scirp.104427-ref7">7</xref>] [<xref ref-type="bibr" rid="scirp.104427-ref8">8</xref>]. At-risk women for endometrial cancer are nulliparous women, advanced age, obesity, diabetes and hypertension, systemic exogenous estrogen therapy, tamoxifen, Lynch syndrome and late menopause [<xref ref-type="bibr" rid="scirp.104427-ref2">2</xref>] [<xref ref-type="bibr" rid="scirp.104427-ref7">7</xref>].</p><p>We here attempted to determine what conditions account for PMB in an outpatient clinic of a University hospital in London.</p></sec><sec id="s2"><title>2. Subjects and Methods</title><p>We retrieved retrospective electronic data of consecutive patients managed for PMB from July 2019 to December 2019. Anonymised sociodemographic data including patient’s age, risk factors, diagnosis and management were reviewed. Data were entered into an excel spreadsheet and statistical analyses performed using the SPSS software package, version 21 (IBM-SPSS Chicago, IL, USA).</p><p>Approval was obtained from the research and innovation directorate of the University Hospital.</p></sec><sec id="s3"><title>3. Results</title><p><xref ref-type="table" rid="table1">Table 1</xref> shows the sociodemographic distribution of the study population. The mean age was 59.63 &#177; 8.3 years. A little over half of the study subjects where Caucasians 52.5% (94). More than half were multiparous 57.0% (102) with a mean parity of 1.81 &#177; 1.67 (mean and standard deviation).</p><p>Clinical presentation and risk factors are represented in <xref ref-type="table" rid="table2">Table 2</xref>. Majority of the patients 77.1% (138) were referred for the first episode of PMB. The most common risk factor was obesity 34.6% (62).</p><p><xref ref-type="table" rid="table3">Table 3</xref> shows the causes of PMB. The diagnosis in order of incidence rate); genital atrophy 37.4%, submucosal fibroid 28.5%, endometrial polyp 20.7%, endometrial hyperplasia 6.7%, and endometrial cancer 5.6%. There was significant association between postmenopausal bleeding with genital atrophy and endo-</p><table-wrap id="table1" ><label><xref ref-type="table" rid="table1">Table 1</xref></label><caption><title> Sociodemographic characteristics</title></caption><table><tbody><thead><tr><th align="center" valign="middle" >Parameter</th><th align="center" valign="middle" ></th><th align="center" valign="middle" >Frequency (%) N = 179</th></tr></thead><tr><td align="center" valign="middle" >Age (years)</td><td align="center" valign="middle" >&lt;50</td><td align="center" valign="middle" >8 (4.5)</td></tr><tr><td align="center" valign="middle" ></td><td align="center" valign="middle" >50 - 59</td><td align="center" valign="middle" >98 (54.7)</td></tr><tr><td align="center" valign="middle" ></td><td align="center" valign="middle" >60 - 69</td><td align="center" valign="middle" >45 (25.1)</td></tr><tr><td align="center" valign="middle" ></td><td align="center" valign="middle" >70 - 79</td><td align="center" valign="middle" >23 (12.8)</td></tr><tr><td align="center" valign="middle" ></td><td align="center" valign="middle" >≥80</td><td align="center" valign="middle" >5 (2.8)</td></tr><tr><td align="center" valign="middle" >Race</td><td align="center" valign="middle" >Asian</td><td align="center" valign="middle" >28 (15.6)</td></tr><tr><td align="center" valign="middle" ></td><td align="center" valign="middle" >Black</td><td align="center" valign="middle" >57 (31.8)</td></tr><tr><td align="center" valign="middle" ></td><td align="center" valign="middle" >Caucasian</td><td align="center" valign="middle" >94 (52.5)</td></tr><tr><td align="center" valign="middle" >Parity</td><td align="center" valign="middle" >Nulliparous</td><td align="center" valign="middle" >57 (31.8)</td></tr><tr><td align="center" valign="middle" ></td><td align="center" valign="middle" >Primipara</td><td align="center" valign="middle" >20 (11.2)</td></tr><tr><td align="center" valign="middle" ></td><td align="center" valign="middle" >Multipara</td><td align="center" valign="middle" >102 (57)</td></tr></tbody></table></table-wrap><table-wrap id="table2" ><label><xref ref-type="table" rid="table2">Table 2</xref></label><caption><title> Clinical presentation and risk factors of postmenopausal bleeding</title></caption><table><tbody><thead><tr><th align="center" valign="middle" >Variable</th><th align="center" valign="middle" ></th><th align="center" valign="middle" >Frequency (%)</th></tr></thead><tr><td align="center" valign="middle" >Presentation</td><td align="center" valign="middle" >Primary</td><td align="center" valign="middle" >138 (77.1)</td></tr><tr><td align="center" valign="middle" ></td><td align="center" valign="middle" >Secondary</td><td align="center" valign="middle" >41 (22.9)</td></tr><tr><td align="center" valign="middle" >Risk factors for PMB</td><td align="center" valign="middle" >Smoking</td><td align="center" valign="middle" >2 (1.1)</td></tr><tr><td align="center" valign="middle" ></td><td align="center" valign="middle" >Family history of endometrial cancer</td><td align="center" valign="middle" >5 (2.8)</td></tr><tr><td align="center" valign="middle" ></td><td align="center" valign="middle" >Hypertension</td><td align="center" valign="middle" >36 (20.1)</td></tr><tr><td align="center" valign="middle" ></td><td align="center" valign="middle" >Obesity</td><td align="center" valign="middle" >62 (34.6)</td></tr><tr><td align="center" valign="middle" ></td><td align="center" valign="middle" >Diabetes</td><td align="center" valign="middle" >26 (14.5)</td></tr><tr><td align="center" valign="middle" ></td><td align="center" valign="middle" >Adenomyosis/endometriosis</td><td align="center" valign="middle" >7 (3.9)</td></tr><tr><td align="center" valign="middle" ></td><td align="center" valign="middle" >Hormone replacement therapy</td><td align="center" valign="middle" >20 (11.2)</td></tr></tbody></table></table-wrap><table-wrap id="table3" ><label><xref ref-type="table" rid="table3">Table 3</xref></label><caption><title> Aetiology, and treatment of post-menopausal bleeding</title></caption><table><tbody><thead><tr><th align="center" valign="middle" ></th><th align="center" valign="middle" >Variable</th><th align="center" valign="middle" >Frequency (%)</th><th align="center" valign="middle" >p-value</th></tr></thead><tr><td align="center" valign="middle" >Pathology</td><td align="center" valign="middle" >Atrophic endometritis and vaginitis</td><td align="center" valign="middle" >67 (37.4)</td><td align="center" valign="middle" >0.004</td></tr><tr><td align="center" valign="middle" ></td><td align="center" valign="middle" >Endometrial cancer</td><td align="center" valign="middle" >10 (5.6)</td><td align="center" valign="middle" >1.000</td></tr><tr><td align="center" valign="middle" ></td><td align="center" valign="middle" >Endometrial hyperplasia</td><td align="center" valign="middle" >12 (6.7)</td><td align="center" valign="middle" >0.007</td></tr><tr><td align="center" valign="middle" ></td><td align="center" valign="middle" >Polyp</td><td align="center" valign="middle" >37 (20.7)</td><td align="center" valign="middle" >0.208</td></tr><tr><td align="center" valign="middle" ></td><td align="center" valign="middle" >Fibroid</td><td align="center" valign="middle" >51 (28.5)</td><td align="center" valign="middle" >0.544</td></tr><tr><td align="center" valign="middle" ></td><td align="center" valign="middle" >Cancer of the cervix</td><td align="center" valign="middle" >2 (1.1)</td><td align="center" valign="middle" >0.204</td></tr><tr><td align="center" valign="middle" >Treatment</td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" ></td><td align="center" valign="middle" >Oestrogen cream</td><td align="center" valign="middle" >32 (17.9)</td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" ></td><td align="center" valign="middle" >Mirena/Norethisterone</td><td align="center" valign="middle" >6 (3.4)</td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" ></td><td align="center" valign="middle" >TAH/BSO</td><td align="center" valign="middle" >11 (6.1)</td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" ></td><td align="center" valign="middle" >Polypectomy</td><td align="center" valign="middle" >37 (20.7)</td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" ></td><td align="center" valign="middle" >TCRF (Transcervical resection of fibroid)</td><td align="center" valign="middle" >11 (6.2)</td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" ></td><td align="center" valign="middle" >None</td><td align="center" valign="middle" >70 (39.1)</td><td align="center" valign="middle" ></td></tr></tbody></table></table-wrap><p>metrial hyperplasia (p &lt; 0.05).</p><p>In terms of treatment, modalities of treatment include polypectomy, estrogen cream, progestin, but 6.1% of the subjects underwent total abdominal hysterectomy and bilateral oophorectomy (TAH/BSO). The rest were managed expectantly.</p></sec><sec id="s4"><title>4. Discussion</title><p>Postmenopausal bleeding (PMB) could present as an ominous sign of an endometrial pathology especially cancer, hence the aphorism “beware of the weeping womb” [<xref ref-type="bibr" rid="scirp.104427-ref10">10</xref>]. It accounts for about 5% of gynaecological referrals and estimated to affect 7% - 15% of postmenopausal women [<xref ref-type="bibr" rid="scirp.104427-ref10">10</xref>] [<xref ref-type="bibr" rid="scirp.104427-ref11">11</xref>].</p><p>In developed countries, the lifetime risk of developing endometrial cancer is 1.1% while the lifetime risk of dying from the disease is 0.4% [<xref ref-type="bibr" rid="scirp.104427-ref14">14</xref>]. In this study, 5.6% of the subjects had endometrial cancer. This is similar to incidence rate reported from similar studies [<xref ref-type="bibr" rid="scirp.104427-ref3">3</xref>] - [<xref ref-type="bibr" rid="scirp.104427-ref12">12</xref>]. Postmenopausal status is a major risk factor for endometrial cancer [<xref ref-type="bibr" rid="scirp.104427-ref10">10</xref>] [<xref ref-type="bibr" rid="scirp.104427-ref13">13</xref>]. With increasing life expectancy, women now live about a third of their lifespan in menopause [<xref ref-type="bibr" rid="scirp.104427-ref15">15</xref>]. Although PMB is not synonymous with endometrial cancer, over 90% of women diagnosed with endometrial cancer had vaginal bleeding [<xref ref-type="bibr" rid="scirp.104427-ref9">9</xref>] [<xref ref-type="bibr" rid="scirp.104427-ref12">12</xref>]. Similarly, we found the mean age of the subjects to be 59 years with 2.8% of them in their 80s. Obesity is an independent risk factor for endometrial cancer and hyperplasia, medical conditions including diabetes and hypertension are prevalent in obese women [<xref ref-type="bibr" rid="scirp.104427-ref4">4</xref>] [<xref ref-type="bibr" rid="scirp.104427-ref13">13</xref>]. This study showed that a little over a third 34.6% of our patients were obese and 20.1% and 14.5% respectively had hypertension and diabetes.</p><p>Management of postmenopausal bleeding is individualized depending on the diagnosis and individual patient characteristics and preferences. In our series, referred patients were seen through the 2-week wait pathway. These included patients with endometrial thickness of more than 5 mm, recurrent PMB or co-existing endometrial pathologies. All the patients had pelvic ultrasound scan. The sensitivity and specificity of TVUS in detecting endometrial pathologies have been investigated in different studies and reported to range between 97% - 98% and 81% - 95% respectively [<xref ref-type="bibr" rid="scirp.104427-ref12">12</xref>]. Diagnostic hysteroscopy and biopsy either in the outpatient setting or under general anaesthetic were done for all the patients meeting the inclusion criteria. Studies have shown hysteroscopy to be reliable and safe in the evaluation of endometrial lesion, it also affords the operator the chance to take directed biopsies and can be employed for “see and treat” [<xref ref-type="bibr" rid="scirp.104427-ref1">1</xref>].</p><p>The most common cause of postmenopausal bleeding in this study was atrophic endometritis and vaginitis in 37.4% of cases while uterine fibroid, endometrial polyp, endometrial hyperplasia and endometrial cancer were reported in 28.5%, 20.7%, 6.7% and 5.6% respectively. This is similar to findings reported in studies [<xref ref-type="bibr" rid="scirp.104427-ref1">1</xref>] [<xref ref-type="bibr" rid="scirp.104427-ref4">4</xref>] [<xref ref-type="bibr" rid="scirp.104427-ref7">7</xref>] [<xref ref-type="bibr" rid="scirp.104427-ref10">10</xref>]. Majority of the patients where managed conservatively. Patients with endometrial cancer were referred to oncology, oestrogen creams were used in the treatment of atrophic vaginitis and polypectomy for polyps. About 39.1% of the patients were either managed expectantly or declined any medical treatment.</p><p>In conclusion, endometrial cancer continues to be diagnosed in women with PMB. This reconfirmation in a single facility is important for making policies in the treatment of PMB. One major limitation of this study is that prognosis for patients managed for endometrial cancer was not explored.</p></sec><sec id="s5"><title>Conflicts of Interest</title><p>We declare no conflict of interest.</p></sec><sec id="s6"><title>Cite this paper</title><p>Mamah, J.E., Onyebuchi, K.A., Onoh, R.C., Okafor, L. and Aliyu, Z. (2020) Pattern of Presentation and Associated Morbidities of Women Presenting with Postmenopausal Bleeding. Open Journal of Obstetrics and Gynecology, 10, 1631-1636. https://doi.org/10.4236/ojog.2020.10110146</p></sec></body><back><ref-list><title>References</title><ref id="scirp.104427-ref1"><label>1</label><mixed-citation publication-type="other" xlink:type="simple">Bar-On, S., Ben-David, A., Rattan, G. and Grisaru, D. (2017) Is Outpatient Hysteroscopy Accurate for the Diagnosis of Endometrial Pathology among Perimenopausal and Postmenopausal Women? Menopause, 25, 160-164.  
https://doi.org/10.1097/GME.0000000000000961</mixed-citation></ref><ref id="scirp.104427-ref2"><label>2</label><mixed-citation publication-type="other" xlink:type="simple">Kitson, S.J. and Crosbie, E.J. (2019) Endometrial Cancer and Obesity. The Obstetrician &amp; Gynaecologist, 21, 1-6. https://doi.org/10.1111/tog.12601</mixed-citation></ref><ref id="scirp.104427-ref3"><label>3</label><mixed-citation publication-type="other" xlink:type="simple">Moodley, M. and Roberts, C. (2004) Clinical Pathway for the Evaluation of Postmenopausal Bleeding with an Emphasis on Endometrial Cancer Detection. Journal of Obstetrics and Gynaecology, 24, 736-741.  
https://doi.org/10.1080/014436104100009394</mixed-citation></ref><ref id="scirp.104427-ref4"><label>4</label><mixed-citation publication-type="other" xlink:type="simple">So, P.L., Sin, W.K., Lee, H.C. and Yeung, K.C. (2012) Evaluation of Recurrent Postmenopausal Bleeding. HKJGOM, 12, 69-79.</mixed-citation></ref><ref id="scirp.104427-ref5"><label>5</label><mixed-citation publication-type="other" xlink:type="simple">Van Hanegem, N., Breijer, M.C., Khan, K.S., Clark, T.J., Burger, M.P., Mol, B.W. and Timmermans, A. (2011) Diagnostic Evaluation of the Endometrium in Postmenopausal Bleeding: An Evidence-Based Approach. Maturitas, 68, 155-164.  
https://doi.org/10.1016/j.maturitas.2010.11.010</mixed-citation></ref><ref id="scirp.104427-ref6"><label>6</label><mixed-citation publication-type="other" xlink:type="simple">Denny, L. and Anorlu, R. (2012) Cervical Cancer in Africa. Cancer Epidemiology, Biomarkers &amp; Prevention, 21, 1434-1438.  
https://doi.org/10.1158/1055-9965.EPI-12-0334</mixed-citation></ref><ref id="scirp.104427-ref7"><label>7</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Brand</surname><given-names> A.H. </given-names></name>,<etal>et al</etal>. (<year>2007</year>)<article-title>The Woman with Postmenopausal Bleeding</article-title><source> Australian Family Physician</source><volume> 36</volume>,<fpage> 116</fpage>-<lpage>120</lpage>.<pub-id pub-id-type="doi"></pub-id></mixed-citation></ref><ref id="scirp.104427-ref8"><label>8</label><mixed-citation publication-type="other" xlink:type="simple">van Hanegem, N., Breijer, M.C., Slockers, S.A., Zafarmand, M.H., Geomini, P.M.A.J., Catshoek, R., et al. (2017) Diagnostic Workup for Postmenopausal Bleeding: A Randomised Controlled Trial. BJOG, 124, 231-240.</mixed-citation></ref><ref id="scirp.104427-ref9"><label>9</label><mixed-citation publication-type="other" xlink:type="simple">De Franciscis, P., Riemma, G., Schiattarella, A., Cobellis, L., Guadagno, M., Vitale, S.G., et al. (2019) Concordance between the Hysteroscopic Diagnosis of Endometrial Hyperplasia and Histopathological Examination. Diagnostics, 9, 142.  
https://doi.org/10.3390/diagnostics9040142</mixed-citation></ref><ref id="scirp.104427-ref10"><label>10</label><mixed-citation publication-type="other" xlink:type="simple">Ghoubara, A., Sundar, S. and Ewies, A.A.A. (2018) Endometrial Pathology in Recurrent Postmenopausal Bleeding: Observational Study of 385 Women. Climacteric, 21, 391-396. https://doi.org/10.1080/13697137.2018.1461825</mixed-citation></ref><ref id="scirp.104427-ref11"><label>11</label><mixed-citation publication-type="other" xlink:type="simple">Smith, P.P., O’Connor, S., Gupta, J. and Clark, T.J. (2014) Recurrent Postmenopausal Bleeding: A Prospective Cohort Study. The Journal of Minimally Invasive Gynecology, 21, 799-803. https://doi.org/10.1016/j.jmig.2014.03.007</mixed-citation></ref><ref id="scirp.104427-ref12"><label>12</label><mixed-citation publication-type="other" xlink:type="simple">Goldstein, R.B., Bree, R.L., Benson, C.B., Benacerraf, B.R., Bloss, J.D., Carlos, R., et al. (2001) Evaluation of the Woman with Postmenopausal Bleeding: Society of Radiologists in Ultrasound-Sponsored Consensus Conference Statement. Journal of Ultrasound in Medicine, 20, 1025-1036.  
https://doi.org/10.7863/jum.2001.20.10.1025</mixed-citation></ref><ref id="scirp.104427-ref13"><label>13</label><mixed-citation publication-type="book" xlink:type="simple">Sean, K. (2018) Endometrial Cancer. In: Edmonds, D.K., Lees, C. and Bourne, T., Eds., Dewhurst’s Textbook of Obstetrics and Gynaecology. 9th Edition. Willey Blackwell, Oxford, 876-883. https://doi.org/10.1002/9781119211457.ch62</mixed-citation></ref><ref id="scirp.104427-ref14"><label>14</label><mixed-citation publication-type="other" xlink:type="simple">ACOG Committee Opinion No. 426 (2009) The Role of Transvaginal Ultrasonography in the Evaluation of Postmenopausal Bleeding. International Journal of Gynecology &amp; Obstetrics, 56, 115-127.</mixed-citation></ref><ref id="scirp.104427-ref15"><label>15</label><mixed-citation publication-type="other" xlink:type="simple">Fagioli, R., Vitagliano, A., Carugno, J., Castellano, G., De Angelis, M.C. and Di Spiezio, A. (2020) Hysteroscopy in Postmenopause: From Diagnosis to the Management of Intrauterine Pathologies. Climacteric, 23, 360-368.  
https://doi.org/10.1080/13697137.2020.1754387</mixed-citation></ref></ref-list></back></article>